Approved Drug Label (PDF)
Boxed Warning
(extensive
additions, please refer to label)
4
Contraindications
(additions
underlined)
FLOWTUSS is contraindicated for:
FLOWTUSS is also contraindicated in
patients with:
Significant respiratory depression.
Acute or severe bronchial asthma in an
unmonitored setting or in the absence of resuscitative equipment.
Known or suspected gastrointestinal
obstruction, including paralytic ileus.
Hypersensitivity to hydrocodone, guaifenesin,
or any of the inactive ingredients in FLOWTUSS
5
Warnings and Precautions
5.10 Risks of Use in Patients with Head Injury, Impaired Consciousness, Increased Intracranial Pressure, or Brain Tumors
(additions
underlined)
Avoid the use of FLOWTUSS in patients with head injury,
intracranial lesions, or a pre-existing increase in intracranial pressure. In patients who may be susceptible to the
intracranial effects of CO2 retention (e.g., those with
evidence of increased intracranial pressure or brain tumors), FLOWTUSS may
reduce respiratory drive, and the resultant CO2 retention can
further increase intracranial pressure.
Furthermore, opioids produce adverse reactions that may obscure the
clinical course of patients with head injuries.
5.5 Risk of Accidental Overdose and Death due to Medication Errors
(additions underlined)
Dosing errors can result in accidental
overdose and death. To reduce the risk
of overdose and respiratory depression, ensure that the dose of FLOWTUSS is
communicated clearly and dispensed accurately.
Advise patients to always use an accurate milliliter
measuring device when measuring and administering FLOWTUSS. Inform patients that household teaspoon is
not an accurate measuring device and such use could lead to overdosage and serious
adverse reactions.For prescriptions where a measuring device is not provided, a
pharmacist can provide an appropriate calibrated measuring device and can
provide instructions for measuring the correct dose.
5.8 Risks from Concomitant Use with Benzodiazepines or other CNS Depressants
(additions
underlined)
…
Patients must not consume alcoholic beverages, or
prescription or non-prescription products containing alcohol, while on FLOWTUSS
therapy. The co-ingestion of alcohol
with FLOWTUSS may result in increased plasma levels and a potentially fatal
overdose of hydrocodone.
(The
following new subsections have been added, please refer to label for more
information)
5.1 Addiction, Abuse, and Misuse
5.2 Life-Threatening Respiratory Depression
5.3 Risks with Use in Pediatric Populations
5.4 Risks with Use in Other At-Risk Populations
5.7 Risks from Concomitant Use or Discontinuation
of Cytochrome P450 3A4 Inhibitors and Inducers
5.9 Risks of Use in Patients with
Gastrointestinal Conditions
5.11 Increased Risk of Seizures in Patients with
Seizure Disorders
5.12 Severe Hypotension
5.13 Neonatal Opioid Withdrawal Syndrome
5.14 Adrenal Insufficiency
5.15 Drug/Laboratory Test Interactions
6
Adverse Reactions
(extensive
additions, please refer to label)
7
Drug Interactions
7.1 Alcohol
(new
subsection added)
Concomitant use of alcohol with FLOWTUSS can result in an
increase of hydrocodone plasma levels and potentially fatal overdose of
hydrocodone. Instruct patients not to
consume alcoholic beverages or use prescription or nonprescription products
containing alcohol while on FLOWTUSS therapy.
7.2 Inhibitors of CYP3A4 and CYP2D6
(new subsection added)
The concomitant use of FLOWTUSS and CYP3A4 inhibitors,
such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents
(e.g. ketoconazole), or protease inhibitors (e.g., ritonavir), can increase the
plasma concentration of hydrocodone, resulting in increased or prolonged opioid
effects. These effects could be more
pronounced with concomitant use of FLOWTUSS and CYP2D6 and CYP3A4 inhibitors,
particularly when an inhibitor is added after a stable dose of FLOWTUSS is
achieved . After stopping a CYP3A4 inhibitor, as the effects of the inhibitor
decline, the hydrocodone plasma concentration will decrease, resulting in
decreased opioid efficacy or a withdrawal syndrome in patients who had
developed physical dependence to hydrocodone.
Avoid the use of FLOWTUSS while taking a CYP3A4 or CYP2D6
inhibitor. If concomitant use is
necessary, monitor patients for respiratory depression and sedation at frequent
intervals.
7.3 CYP3A4 Inducers
(new
subsection added)
The concomitant use of FLOWTUSS and CYP3A4 inducers such
as rifampin, carbamazepine, or phenytoin, can decrease the plasma concentration
of hydrocodone , resulting in
decreased efficacy or onset of a withdrawal syndrome in patients who have
developed physical dependence to hydrocodone. After stopping a CYP3A4 inducer, as the effects of the inducer
decline, the hydrocodone plasma concentration will increase, which could increase or prolong
both the therapeutic effects and adverse reactions, and may cause serious
respiratory depression.
Avoid the use of FLOWTUSS in patients who are taking
CYP3A4 inducers. If concomitant use of a
CYP3A4 inducer is necessary, follow the patient for reduced efficacy.
7.4 Benzodiazepines, and Other CNS Depressants
(additions
underlined)
Due to additive pharmacologic effect, the concomitant use
of benzodiazepines or other CNS depressants, including alcohol, other
sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general
anesthetics, antipsychotics, and other opioids, can increase the risk of
hypotension, respiratory depression, profound sedation, coma, and death. Avoid the use of FLOWTUSS in patients who are
taking benzodiazepines or other CNS depressants, and instruct patients to avoid consumption of alcohol while on
FLOWTUSS.
7.5 Serotonergic Drugs
(new
subsection added)
The concomitant use of opioids with other drugs that
affect the serotonergic neurotransmitter system has resulted in serotonin
syndrome. If concomitant use is
warranted, carefully observe the patient, particularly during treatment
initiation. Discontinue FLOWTUSS if
serotonin syndrome is suspected.
7.6 Monoamine Oxidase Inhibitors (MAOIs)
(additions
underlined)
Avoid the use of FLOWTUSS in patients who are taking
monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14
days. The use of MAOIs or tricyclic
antidepressants with hydrocodone, one of the active ingredients in FLOWTUSS,
may increase the effect of either the antidepressant or hydrocodone. MAOI interactions with opioids may
manifest as serotonin syndrome or opioid toxicity (e.g., respiratory
depression, coma).
7.7 Muscle Relaxants
(new
subsection added)
Hydrocodone may enhance the neuromuscular blocking action
of skeletal muscle relaxants and produce an increased degree of respiratory
depression. Avoid the use of FLOWTUSS in
patients taking muscle relaxants. If
concomitant use is necessary, monitor patients for signs of respiratory
depression that may be greater than otherwise expected.
7.8 Diuretics
(new
subsection added0
Opioids can reduce the efficacy of diuretics by inducing
the release of antidiuretic hormone.
Monitor patients for signs of diminished diuresis and/or effects on
blood pressure and increase the dosage of the diuretic as needed.
7.9 Anticholinergic Drugs
(new
subsection added)
The concomitant use of anticholinergic drugs with
FLOWTUSS may increase risk of urinary retention and/or severe constipation,
which may lead to paralytic ileus. Monitor
patients for signs of urinary retention or reduced gastric motility when
FLOWTUSS is used concomitantly with anticholinergic drugs.
8
Use in Specific Populations
8.1 Pregnancy
(PLLR
conversion, please refer to label)
8.2 Lactation
(PLLR
conversion)
Risk Summary
Because of the potential for serious adverse reactions,
including excess sedation, respiratory depression, and death in a breastfed
infant, advise patients that breastfeeding is not recommended during treatment
with FLOWTUSS.
There are no data on the presence of FLOWTUSS in human
milk, the effects of FLOWTUSS on the breastfed infant, or the effects of
FLOWTUSS on milk production; however, data are available with hydrocodone.
Hydrocodone
Hydrocodone is present in breast milk. Published cases report variable
concentrations of hydrocodone and hydromorphone (an active metabolite) in
breast milk with administration of immediate-release hydrocodone to nursing
mothers in the early post-partum period with relative infant doses of hydrocodone
ranging between 1.4 and 3.7%. There are
case reports of excessive sedation and respiratory depression in breastfed
infants exposed to hydrocodone. No
information is available on the effects of hydrocodone on milk production.
Guaifenesin
No information is available on the levels of guaifenesin
in breast milk or on milk production.
Clinical Considerations
Infants exposed to FLOWTUSS through breast milk should be
monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed
infants when maternal administration of an opioid is stopped, or when
breastfeeding is stopped.
8.3 Females and Males of Reproductive Potential
(PLLR conversion)
Infertility
Chronic use of opioids, such as
hydrocodone, a component of FLOWTUSS, may cause reduced fertility in females
and males of reproductive potential. It
is not known whether these effects on fertility are reversible
8.4 Pediatric Use
(additions
underlined)
FLOWTUSS is not indicated for
use in patients younger than 18 years of age because the benefits of
symptomatic treatment of cough associated with allergies or the common cold do
not outweigh the risks for use of hydrocodone in these patients.
Life-threatening
respiratory depression and death have occurred in children who received
hydrocodone. Because of the
risk of life-threatening respiratory depression and death, FLOWTUSS is
contraindicated in children less
than 6 years of age.
8.5 Geriatric Use
(additions
underlined)
Clinical studies have not been conducted with FLOWTUSS in
geriatric populations.
Use caution when considering the use of
FLOWTUSS in patients 65 years of age or older. Elderly patients may have increased
sensitivity to hydrocodone; greater frequency of decreased hepatic, renal,
or cardiac function; or concomitant disease or other drug therapy.
Respiratory depression is the chief risk for
elderly patients treated with opioids, including FLOWTUSS. Respiratory depression has occurred after
large initial doses of opioids were administered to patients who were not
opioid-tolerant or when opioids were co-administered with other agents that
depress respiration.
Hydrocodone is known to be substantially
excreted by the kidney, and the risk of adverse reactions to this drug may be
greater in patients with impaired renal function. Because elderly patients are more likely to
have decreased renal function, monitor these patients closely for respiratory
depression, sedation, and hypotension.
8.6 Renal Impairment
(additions
underlined)
The pharmacokinetics of FLOWTUSS has not been
characterized in patients with renal impairment. Patients with renal impairment may have
higher plasma concentrations than those with normal function. FLOWTUSS should
be used with caution in patients with severe impairment of renal
function, and patients should be monitored closely for respiratory
depression, sedation, and hypotension.
8.7 Hepatic Impairment
(additions
underlined)
The pharmacokinetics of FLOWTUSS has not been
characterized in patients with hepatic impairment. Patients with severe hepatic impairment may
have higher plasma concentrations than those with normal hepatic function. Therefore, FLOWTUSS should be
used with caution in patients with severe impairment of hepatic function,
and patients should be monitored closely for respiratory depression, sedation,
and hypotension.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
MEDICATION GUIDE
(additions
and revisions, please refer to label)
PATIENT COUNSELING INFORMATION
(extensive
additions, please refer to label)
Approved Drug Label (PDF)
Boxed Warning
(New
section added)
WARNING: RISKS FROM CONCOMITANT USE WITH
BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Concomitant use of opioids with
benzodiazepines or other central nervous system (CNS) depressants, including
alcohol, may result in profound sedation, respiratory depression, coma, and
death. Avoid use of opioid cough medications in patients taking
benzodiazepines, other CNS depressants, or alcohol.
5
Warnings and Precautions
5.1 Risks from Concomitant Use with Benzodiazepines or other CNS Depressants
(subsection
added)
Concomitant use of opioids,
including FLOWTUSS, with benzodiazepines, or other CNS depressants, including
alcohol, may result in profound sedation, respiratory depression, coma, and
death. Because
of these risks, avoid use of
opioid cough medications in patients taking benzodiazepines, other CNS depressants,
or alcohol.
Observational studies have
demonstrated that concomitant use of opioid analgesics and benzodiazepines
increases the risk of drug-related mortality compared to use of opioids alone.
Because of similar pharmacologic properties, it is reasonable to expect similar
risk with concomitant use of opioid cough medications and benzodiazepines,
other CNS depressants, or alcohol.
Advise both patients and
caregivers about the risks of respiratory depression and sedation if FLOWTUSS
is used with benzodiazepines, alcohol, or other CNS depressants.
7
Drug Interactions
7.1 Benzodiazepines, Opioids, Antihistamines, Antipsychotics, Anti-anxiety Agents, or Other CNS Depressants (Including Alcohol)
(additions
underlined)
The use of benzodiazepines,
opioids, antihistamines, antipsychotics, anti-anxiety agents, or other CNS
depressants (including alcohol) concomitantly with FLOWTUSS may cause an
additive CNS depressant effect, profound sedation, respiratory depression, coma,
and death and should be avoided.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
17 PATIENT COUNSELING INFORMATION
(additions
underlined)
…
Interactions with Benzodiazepines and Other
Central Nervous System Depressants
Inform patients and
caregivers that potentially fatal additive effects may occur if FLOWTUSS is
used with benzodiazepines or other CNS depressants, including alcohol. Because
of this risk, patients should avoid concomitant use of FLOWTUSS with
benzodiazepines or other CNS depressants, including alcohol.
…
MEDICATION GUIDE
(new
section added, please refer to label)